Loading organizations...
Relievant Medsystems develops medical devices for chronic low back pain. The FDA-cleared Intracept Procedure is a minimally invasive treatment for vertebrogenic pain. It ablates the basivertebral nerve with radiofrequency energy, disrupting pain signals from damaged vertebral endplates, offering a targeted solution where conservative therapies fail.
Founded in 2006 by Jim Peacock, Rex Peters, Richard Pellegrino, and Samit Patel, Relievant identified a critical treatment gap. Chronic low back pain patients with vertebral endplate issues lacked durable solutions, inspiring their pioneering intervention focused on the basivertebral nerve.
Relievant serves patients with chronic vertebrogenic low back pain unresponsive to conventional care. Its vision: establish the Intracept Procedure as a standard of care. It aims to provide lasting pain relief, enhancing functional capabilities and quality of life for an underserved population.
Relievant Medsystems has raised $453.0M across 11 funding rounds.
Relievant Medsystems has raised $453.0M in total across 11 funding rounds.
Relievant Medsystems has raised $453.0M across 11 funding rounds. Most recently, it raised $50.0M Series G in April 2023.
Relievant Medsystems is a privately held medical device company founded in 2006 that developed the Intracept® System, a minimally invasive procedure targeting the basivertebral nerve to provide lasting relief for patients with chronic vertebrogenic low back pain (CLBP) originating from degenerative disc disease with Modic changes.[1][2][3] The company serves spine surgeons, orthopedic surgeons, neurological surgeons, and interventional pain physicians, addressing a significant unmet need for millions suffering from CLBP where traditional treatments like surgery or opioids fall short.[1][3] With estimated annual revenue of $78.8M, 251 employees, and $271M in total funding, Relievant demonstrated strong growth before its acquisition by Boston Scientific in November 2023 for an upfront $850M plus contingent payments.[1][4]
The Intracept procedure delivers targeted energy to block pain signal transmission in the spine, backed by clinical trials showing long-term durability, and gained expanded U.S. coverage from major payers like Anthem, Humana, and Cigna, reaching over 150 million lives.[3][4]
Relievant Medsystems was founded in 2006 in Minneapolis, MN, with additional offices in Sunnyvale, CA, focusing on innovative solutions for chronic low back pain.[1][2] Key leaders include President & CEO Tyler Binney and Chief Medical Officer Ray Baker, who drove the development of the Intracept System amid growing recognition of vertebrogenic pain as a distinct CLBP subtype identifiable by Modic changes on MRI.[1][3]
The idea emerged from the need for targeted, minimally invasive therapies beyond conservative care or fusion surgery; early traction came from FDA clearance as the only device for vertebrogenic pain treatment, clinical validations, and $58M in venture funding in 2018, building toward commercial scale and payer adoption.[1][4]
Relievant rides the wave of precision pain management in medtech, targeting vertebrogenic pain—a biomarker-driven subset of the $100B+ CLBP market—amid rising demand for non-opioid, evidence-based alternatives post-opioid crisis.[1][3][4] Timing aligns with FDA clearances, payer policies favoring procedures with proven outcomes, and medtech consolidation, as seen in Boston Scientific's acquisition to bolster its neuromodulation portfolio with multi-target pain solutions.[4][5]
Market forces like aging populations, diagnostic advances (e.g., Modic changes), and coverage for 150M+ lives amplify its influence, shifting ecosystems toward basivertebral nerve interventions and integrating into larger platforms for global reach.[4]
Post-acquisition by Boston Scientific in 2023, Relievant’s Intracept technology integrates into a leading medtech giant’s chronic pain offerings, with expected accretion to earnings by 2025 and sales-contingent milestones driving expansion.[4] Trends like payer expansions, further clinical data, and AI-enhanced diagnostics will accelerate adoption, potentially evolving its influence from niche innovator to standard-of-care in vertebrogenic pain therapies worldwide.[3][4][5] This positions Relievant to transform millions more lives, reinforcing its origins in targeted spine solutions.
Relievant Medsystems has raised $453.0M in total across 11 funding rounds.
Relievant Medsystems's investors include Kevin Reilly, Canaan Partners, Endeavour Vision, Lightstone Ventures, Morgenthaler Ventures, New Enterprise Associates, Vensana Capital, Justin Klein, Questa Capital, Alexander Schmitz, Emergent Ventures, RK Mellon.
